According to Avidity Biosciences's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 205.72. At the end of 2023 the company had a P/S ratio of 75.0.
Year | P/S ratio | Change |
---|---|---|
2023 | 75.0 | -53.12% |
2022 | 160 | 33.76% |
2021 | 120 | -15.29% |
2020 | 141 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Pfizer PFE | 2.69 | -98.69% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 2.32 | -98.87% | ๐ฌ๐ง UK |
Sarepta Therapeutics
SRPT | 9.83 | -95.22% | ๐บ๐ธ USA |
PTC Therapeutics
PTCT | 2.40 | -98.83% | ๐บ๐ธ USA |
Fate Therapeutics
FATE | 13.1 | -93.61% | ๐บ๐ธ USA |
Acorda Therapeutics
ACOR | 0.1331 | -99.94% | ๐บ๐ธ USA |
Acceleron Pharma XLRN | N/A | N/A | ๐บ๐ธ USA |
Catalyst Pharmaceuticals CPRX | 4.82 | -97.66% | ๐บ๐ธ USA |